Finanzas de Lisata Therapeutics Inc (LSTA)LSTALisata Therapeutics Inc

Lisata Therapeutics, Inc. (LSTA) generates its revenue primarily from PCT Segment, which accounts for 100.0% of total sales, equivalent to $7.92M. Understanding this concentration is critical for investors evaluating how LSTA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Lisata Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -99.89%, provide a clear picture of how effectively LSTA converts its operational activities into shareholder value.

In the context of the broader market, LSTA competes directly with industry leaders such as GTBP and CLRB. With a market capitalization of $11.02M, it holds a significant position in the sector. When comparing efficiency, LSTA's gross margin of N/A stands against GTBP's N/A and CLRB's N/A. Such benchmarking helps identify whether Lisata Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Lisata Therapeutics has shown significant financial struggles, with total revenue of only 1,000,000 USD reported in Q4 2024 and consistent net losses, including -4,489,000 USD in Q1 2026. The gross margin is currently at 100% for Q4 2024, but this is not sustainable given the ongoing losses.